Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Sumie, Shuji ^a   Kawaguchi, Takumi ^a   Kuromatsu, Ryoko ^a   Takata, Akio ^a   Nakano, Masahito ^a   Satani, Manabu ^a   Yamada, Shingo ^a   Niizeki, Takashi ^a   Torimura, Takuji ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; BODY MASS; CANCER GRADING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PREVALENCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; AGED; BLOOD; CHEMISTRY; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

HEPATITIS C VIRUS;

ADIPONECTIN; AGED; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR WEIGHT;

EID: 81055145083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026840     Document Type: Article

References (41)

1. Bosch FX, Ribes J, Diaz M, Cleries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
2. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, et al. (2004) Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127: S17-26.
3. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO, (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91: 421-430.
4. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, (2002) Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36: 729-736.
5. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE, (2008) Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 48: 80-87.
6. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, et al. (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42: 218-224.
7. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923.
8. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51: 1972-1978.
9. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, et al. (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135: 111-121.
10. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, et al. (2008) Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 6: 459-464.
11. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, et al. (2010) Adiponectin Modulates C-Jun N-Terminal Kinase and Mammalian Target of Rapamycin and inhibits hepatocellular carcinoma. Gastroenterology.
12. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278: 40352-40363.
13. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279: 1304-1309.
14. Adachi M, Brenner DA, (2008) High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47: 677-685.
15. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al. (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699-5704.
16. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, et al. (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89: 1160-1163.
17. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS, (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97: 1688-1694.
18. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, et al. (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11: 466-472.
19. Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, et al. (2007) Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 47: 191-202.
20. Tietge UJ, Boker KH, Manns MP, Bahr MJ, (2004) Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 287: E82-89.
21. Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, et al. (2005) Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 258: 274-280.
22. Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, et al. (2002) Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 235: 722-730.
23. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, et al. (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33: 1080-1086.
24. Seker M, Bilici A, Sonmez B, Ustaalioglu BB, Gumus M, et al. (2010) The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol 27: 1319-1323.
25. Barresi V, Tuccari G, Barresi G, (2009) Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology 41: 533-538.
26. Liver Cancer Study Group of Japan (2010) General rules for the clinical and pathological study of primary liver cancer. 3nd English ed Tokyo Kanehara & Co., Ltd.
27. Edmondson HA, Steiner PE, (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503.
28. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526.
29. Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, et al. (2010) Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 53: 827-833.
30. Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, et al. (2008) Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 103: 605-614.
31. Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, et al. (2005) Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 43: 235-242.
32. Kojiro M, (2005) Histopathology of liver cancers. Best Pract Res Clin Gastroenterol 19: 39-62.
33. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y, (2005) Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333: 79-87.
34. Nakashima O, Sugihara S, Kage M, Kojiro M, (1995) Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 22: 101-105.
35. Himeno H, Enzan H, Saibara T, Onishi S, Yamamoto Y, (1994) Hitherto unrecognized arterioles within hepatocellular carcinoma. J Pathol 174: 217-222.
36. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N, (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
37. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, et al. (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77.
38. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, et al. (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101: 2476-2481.
39. Man K, Ng KT, Xu A, Cheng Q, Lo CM, et al. (2010) Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 16: 967-977.
40. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, et al. (2003) Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085.
41. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, et al. (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960.